REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, +30

New England Journal of Medicine

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Lulu Bravo, Igor Smolenov, Htay Htay Han, +44

The Lancet

VaccinologyVaccine SafetyVaccinationVaccine DevelopmentImmunology +7

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

Sumathi Sivapalasingam, Rabih Slim, Romana Hosain, +8

The Lancet Infectious Diseases

VaccinationVaccine DevelopmentVaccine TargetCo-formulated CocktailImmunology +7

Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase®

Ulrich Vogel, John van Stekelenborg, Brian Dreyfus, +4

Drug Safety

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya Menon, +30

The Journal of Infectious Diseases

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, +36

Viral LoadCovid-19 PandemicClinical TrialsCovid-19 OutpatientsVaccine Trial +10

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial

Sumathi Sivapalasingam, David J. Lederer, Rafia Bhore, +37

Clinical Infectious Diseases

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

Sumathi Sivapalasingam, David J. Lederer, Rafia Bhore, +37

Randomized Placebo-controlled TrialInflammatory ResponseClinical TrialsSarilumab 400Inflammatory Marker +10

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 Results

Thomas Norton, Shazia Ali, Sumathi Sivapalasingam, +33

Antibody CombinationRegen-cov Antibody CombinationCovid-19 PandemicClinical EpidemiologyOutpatient Setting +9

Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19

Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya Menon, +29

Cas+imd Vs PlaceboClinical Infectious DiseaseHospitalized PatientsImmunotherapyImmunodeficiencies +12